Protara Therapeutics, Inc.
Company Stats
- Market Cap
- $180.2M
- as of Sep 30, 2026
- Shares Outstanding
- 59.1M
- Free Float
- 84.6%
Income Statement
- Operating Income
- -$64.5M
- Net Income
- -$57.4M
- EBITDA
- -$64.2M
Cash Flow
- Free Cash Flow
- -$56.5M
- FCF Yield
- -31.3%
- Owner FCF Yield
- -33.4%
Balance Sheet
- Cash & Equivalents
- $49.7M
Returns & Capital
- SBC, 3Y Avg
- $4.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$56.5M | — |
| FY2024 | — | -$35.9M | — |
| FY2023 | — | -$37.6M | — |
| FY2022 | — | -$26.6M | — |
| FY2021 | — | -$35.1M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Protara Completes $8.75 Million Novex Asset Purchase
Stronger demand supports expansion as pricing diverges